STOXIL
LOE ApproachingNDAOPHTHALMICOINTMENT
Approved
Sep 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STOXIL is an ophthalmic ointment approved in 1967 for viral eye infections, specifically herpes simplex keratitis. The exact mechanism of action is not specified in available data, but the product represents a legacy small-molecule antiviral for corneal disease. It is formulated as a topical ointment for direct ocular application.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should anticipate defensive positioning and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STOXIL offers limited career upside given the LOE-approaching lifecycle and minimal linked job openings. This role is better suited for professionals seeking stable portfolio management or transition toward generic/off-patent defense strategies.
Brand ManagerProduct Manager
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.